基于资产专用性的企业融资决策研究

本文采用Williamson的思路,建立了资产专用性与交易成本、生产成本因素在内的综合交易成本分析模型。分析发现,相对于债务融资而言,股权融资有利于避免按市场规则强行清算带来的专用性资产价值损失,运用包络定理证明专用性程度高的资产具有削减生产成本的作用,专用性程度高的资产以股权融资为佳。     

新国际贸易与经济地理理论及其发展——2008年诺贝尔经济学奖得主的理论贡献

2008年诺贝尔经济学奖得主克鲁格曼将规模经济、产品差异与运输成本引入一般均衡分析模型,其开创性的研究使贸易理论和经济地理这两个曾经是相互独立的经济学分支融合到一起,成为新贸易理论发展的先导;作为创始人,他还将新经济地理学融入了主流经济学。此外,克鲁格曼还与几位合作者打通了新经济地理学与城市地区经济学传统研究之间的通道,并对国际货币经济学做出了重要贡献。     

A strategic market game with seigniorage costs of Fiat money

Summary. A model that includes the cost of producing money is presented and the nature of the inefficient equilibria in the model are examined. It is suggested that if one acknowledges that transactions are a form of production, which requires the consumption of resources, then the concept of Pareto optimality is inappropriate for assessing efficiency. Instead it becomes necessary to provide an appropriate comparative analysis of alternative transactions mechanisms in the appropriate context. Received: September 5, 2000; revised version: May 3, 2001     

Cost data quality considerations for eco-efficiency measures

Cost data are a central aspect of eco-efficiency measures, either as means to assess value of production, or, more directly, as one dimension of the efficiency ratio. Several aspects may affect the quality of cost data, among them definitions, time and space, and confidentiality issues. Somewhat surprisingly, cost data quality has received little attention in the field of sustainability and eco-efficiency so far. Even worse, perhaps, is the lack of tools suitable for a cost data quality assessment and management.This paper discusses parameters that affect cost data quality, and will then propose a pedigree matrix as a tool designed for managing cost data quality issues. The application of the matrix is described, also in combination with a previously proposed, and broadly used, pedigree matrix for environmental data quality management.     

计算机软件价值评估探讨

计算机软件是计算机技术能创造巨大经济效益的关键部分。正确地认识计算机软件的巨大经济价值,是软件产业发展的必要条件。     

A signaling model of environmental overcompliance

We present a theory of unilateral regulatory overcompliance as a signaling device. Firms that have a competitive advantage in the use of a cleaner but more costly technology overcomply in order to signal to an imperfectly informed, benevolent government that compliance costs are low, thereby triggering tougher regulation. We identify the conditions under which such an overcompliance signaling equilibrium arises, showing that there may be over-overcompliance in that firms may overcomply even when tougher regulation is not socially desirable. We also discuss the differential implications of the signaling theory as compared to other theories of unilateral regulatory overcompliance.     

Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia,neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia

Abstract

Objective: The study aim was to assess costs of haematological adverse events (AE) related to pharmacologic treatment of chronic myeloid leukaemia (CML) patients.

Methods: This was a retrospective cohort study using patient records of adults (n=91) with chronic-phase CML treated at a single university medical centre in the Netherlands. Occurrence of grade III/IV haematological AEs, defined according to CTC-NCI guidelines criteria, was derived from the laboratory registration. Mean age at time of diagnosis was 48 years; 56% male. A healthcare perspective was adopted. Cost estimates are presented in 2006 euros.

Results: Average cost of an episode of anaemia was €1,572, of thrombocytopenia €2,955, and of neutropenia €1,152. The mean cost of febrile neutropenia amounted to €2,462.

Conclusions: Treatment costs of AEs varied considerably. However, apart from the cost of anaemia, the results presented seem to be in line with information from the international literature. The key limitations of the study concern the relatively small cohort of patients at a single centre, the retrospective design and the various treatment regimens of CML during the follow-up.     

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts

Abstract

Objective:

To study outcomes of multiple sclerosis (MS) patients treated with either glatiramer acetate (Copaxone) or interferon beta-1a for once-weekly, intramuscular administration (Avonex).

Methods:

An ‘intent-to-treat’ (ITT) cohort (n?=?1282) was established, consisting of patients diagnosed with MS who began therapy on either glatiramer acetate (GA) or intramuscular interferon beta-1a (IFN beta-1a-IM) and had continuous insurance coverage from 6 months before to 24 months after the date when they began taking the medication. A ‘persistent use’ (PU) cohort (n?=?639) was also constructed, consisting of individuals who, in addition to the criteria listed above, had a claim for GA or IFN beta-1a-IM within 28 days of the end of the 2-year post-period. Data were obtained from the i3 InVision Data Mart Database from July 2001 to June 2006. Multivariate regressions were used to examine both the 2-year total direct medical costs and the likelihood of relapse associated with the use of each of these alternative MS medications. A relapse was defined as either being hospitalized with a principal diagnosis of MS or having an outpatient visit with a MS diagnosis followed within 7 days by a claim for a corticosteroid. All regressions controlled a wide range of factors that may potentially affect outcomes.

Results:

In the ITT cohort, patients who started therapy on GA had a significantly lower 2-year risk of relapse (10.01 vs. 5.18%; p?=?0.0034) as well as significantly lower 2-year total medical costs ($44,201 vs. $41,121; p?=?0.0294). In the PU cohort, patients who used GA also had a significantly lower 2-year risk of relapse (7.25 vs. 2.16%; p?=?0.0048) as well as significantly lower total medical costs ($67,744 vs. 63,714; p?=?0.0445).

Limitations:

The analyses relies on an administrative claims database of an insured population and hence, may not be generalizeable to other populations. In addition, such a database precludes measurement of lost work time, unemployment, caregiver burden or other costs associated with MS.

Conclusions:

Results from this study indicate that the use of GA is associated with significantly lower probability of relapse as well as significantly lower 2-year total direct medical costs than IFN beta-1a-IM.